Adverse effects of antibiotics: proportion of participants with one or more serious adverse event · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Ciprofloxacin showed no clear difference in adverse effects of antibiotics: proportion of participants with one… compared with placebo added to cycled and culture‐based inhaled tobramycin (TNS)… (moderate certainty).
1 finding from 1 review
Total systemic steroid dose · mild asthma
1 finding from 1 review
Adverse events · mild asthma
As‐required FABA/ICS inhalers showed no clear difference in adverse events compared with regular inhaled steroid (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · mild asthma
As‐required FABA/ICS inhalers showed no clear difference in exacerbations requiring systemic steroid compared with regular inhaled steroid (low certainty).
1 finding from 1 review
Hospital admission, ED and urgent care visits · mild asthma
As‐required FABA/ICS inhalers may leads to lower hospital admission, ED and urgent care visits compared with regular inhaled steroid (low certainty).
1 finding from 1 review
Asthma control · mild asthma
1 finding from 1 review
Mortality within the trial period · preterm infants (< 37 weeks GA) at risk of chronic lung disease
Summary of findings table ‐ Salbutamol showed no clear difference in mortality within the trial period compared with placebo (low certainty).
1 finding from 1 review
Chronic lung disease · preterm infants (< 37 weeks GA) at risk of chronic lung disease
Summary of findings table ‐ Salbutamol showed no clear difference in chronic lung disease at 28 days compared with placebo (low certainty).
1 finding from 1 review
Hypokalaemia · preterm infants (< 37 weeks GA) at risk of chronic lung disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pneumothorax · preterm infants (< 37 weeks GA) at risk of chronic lung disease
1 finding from 1 review
Annual Exacerbation Rates · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Change in quality of life: SGRQ Scale: 0 to 100 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Pneumonia · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS may leads to higher pneumonia compared with placebo (low certainty).
1 finding from 1 review
Oropharyngeal candidiasis · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS probably leads to higher oropharyngeal candidiasis compared with placebo (moderate certainty).
1 finding from 1 review
Outcomes (weighted · stable COPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate‐to‐severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower moderate‐to‐severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline (lower scores indicate better HRQoL) · stable COPD
Triple therapy leads to higher respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline… compared with LABA/LAMA combination (high certainty).
1 finding from 1 review